What you should know about the patients in these studies:
In two 16-week clinical trials with DUPIXENT when used alone compared to a placebo:
Most common side effects were injection site reactions, eye and eyelid inflammation, including redness, swelling and itching, and cold sores in your mouth or on your lips.
Results when DUPIXENT was used alone†‡ every other week for 16 weeks comparedto patients taking placebo.
†Results from “DUPIXENT alone” derived from averaging results from 2 studies
‡All patients used a daily moisturizer
Results when DUPIXENT was used every other week for 16 weeks topical corticosteroids compared to patients taking topical corticosteroids.with
Patients experienced a significant itch reduction while participating in clinical trials.
DUPIXENT started working quickly and continued to show results, with the majority of patients seeingsignificant skin improvement and itch reduction at 1 year of treatment when used with topical corticosteroids.
These results show the percentage of patients who experienced the followingresults at 1 year (52 weeks) while taking DUPIXENT once every other week while using topical corticosteroids compared to patients taking placebo and topical corticosteroids.
The safety profile of DUPIXENT and topical corticosteroids through Week 52 (trial 3) was generallyconsistent with the safety profile observed at Week 16.
The initial dose of DUPIXENT is two injections (600 mg) under the skin at different injection sites. After that, it is taken as one 300 mg injection every other week at different injection sites. DUPIXENT can be used with or without topical corticosteroids.
Talk to your healthcare professional and download the detailed Instructions for Use for information on how to prepare and inject DUPIXENT and how to properly store and dispose used DUPIXENT Pre-Filled Syringes. Do not try to inject DUPIXENT until you have been shown the right way by your healthcare provider.Find Out More
Use this tool to easily find nearby specialists with experience in treating adults with uncontrolled moderate-to-severe eczema (atopic dermatitis).
Sanofi US and Regeneron do not endorse or recommend any particular physician, and search results do not include a comprehensive list of doctors in your area.